Cardiology @StanCVFellows | Dad x 4 | CVD Epigenetics & Metabolism | @BrighamMedRes ‘24 | @AvHStiftung '22 | @UABMSTP '20 | @ucdavis BME '13 | Clemson '11
Stanford, CA
Joined September 2011
- Tweets933
- Following606
- Followers894
- Likes1.7K
CardioGenetics: now available on iOS. I hope you enjoy it as much as I do!
lnkd.in/giSsq358
I built this app because I kept encountering into the same challenge for inherited cardiovascular disease clinic that the information I needed is pretty scattered.
I hope what makes it special is not simply the compilation of tools, but the way they are linked. Instead of jumping between websites, PDFs, and notes, the work flows from diagnosis, risk stratification, genotype-specific guidance, and trial screening in a single workflow.
Mark Pepin MD, PhD, FESC retweeted
Danicamtiv selectively boosts cardiac myosin function in vitro and was generally well tolerated in DCM patients. Echo results suggest improved contractile function, especially in MYH7 and TTN groups. jacc.org/doi/10.1016/j.jacc.…
#JACC #cvEcho #cvDCM #PrecisionMedicine
Mark Pepin MD, PhD, FESC retweeted
Nominations are invited for TWO new council members + ONE Early Career Investigator council member. If you are currently a member of ISHR, and interested in being more involved in the Society, please consider, by 31 Dec! ishr-europe.org/council-nomi… #ISHR #research #society #ECI
Mark Pepin MD, PhD, FESC retweeted
Top #Altmetric 2025: 5️⃣
MP Snyder et al (@StanfordMed) show that the SCFAs propionate and butyrate have differential effects on chromatin remodelling, contributing to selective histone acylation.
nature.com/articles/s42255-0…
Excited to share our new review with Johannes Backs on how metabo epigenetic circuits encode gene programs that drive heart failure development and progression.
link.springer.com/article/10…
Translating these insights into therapy will require disease relevant discovery platforms and more selective epigenetic drugs, including isoform specific HDAC inhibitors and EZH2 targeted agents.
Mark Pepin MD, PhD, FESC retweeted
Delighted to share our study led by @ZhiYu_ACGT & with @Dr_RajatGupta prioritizing putative mediators of systemic consequences of clonal hematopoiesis across cohorts using two proteomics platforms, with murine validation nature.com/articles/s41467-0… @NatureComms
Mark Pepin MD, PhD, FESC retweeted
🚨Medical students: Interested in spending a year in another city, making new friends, learning new skills in biomedical research applied to CVD, and acquiring a new nationwide mentorship network? Apply to @SarnoffCardio!
sarnofffoundation.org/
Mark Pepin MD, PhD, FESC retweeted
🚨We are recruiting🚨
We are currently recruiting for a trainee board member position beginning at the 2026 SHVM Meeting in Osaka, Japan.
We are seeking a passionate early career researcher who is enthusiastic about contributing to the SHVM community 🫀
What began as a fun consulting opportunity evolved into a mission to set a standard for rigor and accountability for ambient AI scribes. frontiersin.org/journals/art…
AI notes had more hallucinations (31% vs 20%). And yet, blinded reviewers still preferred the AI notes overall (47% vs 39%).
This work shows that while AI notes are comparable, this validation framework is essential for iterative improvement and accountability.